Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
High-quality baobab oil sourced in collaboration with UNCCD and the Great Green Wall Initiative
The new ECO grade is made using renewable feedstock
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
The product is expected to be launched in FY25
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Subscribe To Our Newsletter & Stay Updated
